drugset / Trial / NCT07318259
Study of Ultra-Fast BCMA/CD70 CAR-T Therapy for Refractory SLE
NaSingle-groupOpen-labelTreatment
Summary
This is an investigator-initiated trial aimed at assessing the safety and efficacy of ultra-fast autologous BCMA/CD70-targeted CAR-T cells in the treatment of refractory systemic lupus erythematosus.
Timeline
- Start
- 2026-01-26
- Primary completion
- 2026-07
- Completion
- 2028-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BCMA/CD70 CAR-T cells | Cell therapy | 150000 cells/kg | — |
| Subject | BCMA/CD70 CAR-T cells | Cell therapy | 500000 cells/kg | — |
| Subject | BCMA/CD70 CAR-T cells | Cell therapy | 1e+06 cells/kg | — |